StockLens
StockLens
EXEL

Exelixis ranks top 2% on fundamentals and top 8% on price trend

A metal scissor-lift platform sits on a stainless-steel workbench, holding a tray filled with rows of small glass vials with blue caps. Around it are amber bottles, test tube racks, and glassware, set in a bright laboratory with large windows and stainless-steel cabinetry.

By StockLens

October 15, 2026

2 min read

A synthesis of StockLens's multi-domain algorithmic analysis.

80
Solid
EXEL

Exelixis, Inc.

Source as of October 15, 2026

Domain Read

Fundamental
88
Exceptional domain read
Technical
83
Solid domain read
Risk
87
Exceptional domain read
Sentiment
47
Cautionary domain read
Macro
71
Solid domain read

Key takeaways

  • Operating margin is 39.9% and net profit margin 35.3% over the trailing twelve months, with the operating margin above the 38.7% top-decile mark of its peer group of 30 global large-cap companies in biotechnology.
  • Shares stand 22.8% above their 200-session average (adjusted closes through Oct 14, 2026).
  • Return on invested capital is 42.1% over the trailing twelve months, above the 24.1% top-decile mark of the same peer group.

Exelixis' overall StockLens score ranks in the top 2%, with strength in both fundamentals (top 2%) and price trend (top 8%). The ranks cover the 2,156 US-listed companies StockLens analyzed on Oct 15, 2026.

What StockLens measured

Fundamentals

Net income per share grew 237.7% over 3 years, above the 133.3% upper-quartile mark of its peer group of 15 global large-cap companies in biotechnology.

Price trend

Shares are up 9.5% over the last 63 trading sessions. Shares stand at their 52-week closing high.

Context from the record

Dated company events from public sources, listed for reference.

On August 5, 2026, the company said total revenues for the quarter ended June 30, 2026 were $628.7 million.1 On August 5, 2026, the company said it recognized $7.8 million in revenues during the six months ended June 30, 2026 in connection with an $8.0 million commercial milestone payment from Takeda.2

How StockLens scores: every company is scored by the same quantitative engine across five domains (Fundamental, Technical, Risk, Sentiment, Macro), combined into one composite and read through the archetype lens that fits its business model.

This is not investment advice; it is an algorithmically generated analysis produced by StockLens's quantitative and agentic AI models.

Sources

Scores and grades reflect StockLens's proprietary model, as of October 15, 2026.

  1. Earnings release (Form 8-K, Exhibit 99.1), August 5, 2026 · Exelixis, Inc. · Published August 5, 2026↩
  2. Quarterly report (Form 10-Q), filed August 5, 2026 · Exelixis, Inc. · Reporting period ended July 3, 2026↩
How StockLens reads Exelixis, Inc.

Core Tension

Tempered factor

Current Ratio: Mitigated: Strong liquidity: Operating Cash Flow to Current Liabilities > 0.4

Tempered factor

Debt-to-Equity: Mitigated: Strong debt service capability: Interest Coverage Ratio > 3.0

Tempered factor

Equity Dilution: Mitigated: Justified dilution: Positive Free Cash Flow Growth AND Share Count Growth < 10%

Tempered factor

Sloan Ratio: Mitigated: Conservative accounting: Negative Sloan Ratio AND Income Quality > 1.0

Uncertainty

Sentiment carries lower confidence than the headline read.

Analyze EXEL in StockLens

Run a fresh StockLens analysis of Exelixis, Inc. (EXEL).

Tags

EXEL
Healthcare
Biotechnology
Deep Dive

Related articles

A person in a white coat and blue gloves uses a pipette on a small glass vial on a metal counter. Trays of similar vials sit beside it, with large stainless steel machinery and bright windows illuminated by daylight in the background.
ADMA

ADMA Biologics ranks top 12% on fundamentals and top 13% on price trend

ADMA Biologics' overall StockLens score ranks in the top 2%, with strength in both fundamentals (top 12%) and price trend (top 13%). The ranks cover the 2,156 US-listed companies StockLens analyzed on Oct 8, 2026.

Oct 8, 2026
Back to Articles